Publication: Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy
Loading...
Open/View Files
Date
2016
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Taylor & Francis
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Mikucki, Maryann E., Joseph J. Skitzki, John G. Frelinger, Kunle Odunsi, Thomas F. Gajewski, Andrew D. Luster, and Sharon S. Evans. 2016. “Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy.” Oncoimmunology 5 (5): e1116675. doi:10.1080/2162402X.2015.1116675. http://dx.doi.org/10.1080/2162402X.2015.1116675.
Abstract
ABSTRACT Promising cancer immunotherapeutics depend on mobilization of cytotoxic T cells across tumor vascular barriers through mechanisms that are poorly understood. Recently, we discovered that the CXCR3 chemokine receptor uniquely functions as the master-regulator of cytotoxic CD8+ T cell extravasation and tumor control despite the multiplicity of chemokines available in the tumor landscape.
Description
Other Available Sources
Research Data
Keywords
Adoptive T cell transfer, cancer immunotherapy, chemokine receptor, CXCR3, T cell trafficking, tumor vessels
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service